Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edicotinib - Janssen Research & Development

Next Previous
Drug Profile

Edicotinib - Janssen Research & Development

Alternative Names: Edicotinib hydrochloride; JNJ-244; JNJ-40346527; JNJ-40346527-AAC-G-002; JNJ-527; PRV 6527

Latest Information Update: 28 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development; OHSU Knight Cancer Institute; Oregon Health & Science University; Provention Bio; The Leukemia & Lymphoma Society
  • Class Anti-inflammatories; Antidementias; Antineoplastics; Antirheumatics; Cyclohexanes; Imidazoles; Small molecules
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • Phase I/II Cognition disorders
  • No development reported Acute myeloid leukaemia; Adenocarcinoma
  • Discontinued Hodgkin's disease; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Adenocarcinoma(First-line therapy, Late-stage disease) in USA (PO)
  • 30 Jan 2024 M.D. Anderson Cancer Center completes a phase I trial in Adenocarcinoma (First-line therapy, Late-stage disease) in USA (IV) (NCT03177460)
  • 27 Apr 2023 Provention Bio has been acquired by Sanofi

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top